These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37939991)

  • 1. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
    Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
    Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
    Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
    Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
    ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
    Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sacubitril-valsartan on aging-related cardiac dysfunction.
    Telesca M; De Angelis A; Donniacuo M; Bellocchio G; Riemma MA; Mele E; Canonico F; Cianflone E; Torella D; D'Amario D; Patti G; Liantonio A; Imbrici P; De Luca A; Castaldo G; Rossi F; Cappetta D; Urbanek K; Berrino L
    Eur J Pharmacol; 2024 Sep; 978():176794. PubMed ID: 38968980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
    Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
    Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sacubitril/valsartan attenuates left ventricular remodeling and improve cardiac function by upregulating apelin/APJ pathway in rats with heart failure].
    Liu HZ; Gao CY; Yuan F; Xu Y; Tian H; Wang SQ; Zhang PF; Shi YN; Wei JJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jul; 50(7):690-697. PubMed ID: 35856226
    [No Abstract]   [Full Text] [Related]  

  • 8. A rat model of metabolic syndrome-related heart failure with preserved ejection fraction phenotype: pathological alterations and possible molecular mechanisms.
    Shi Y; Liu C; Yang C; Qiao W; Liu Y; Liu S; Dong G
    Front Cardiovasc Med; 2023; 10():1208370. PubMed ID: 37469482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ling-Gui-Qi-Hua formula alleviates left ventricular myocardial fibrosis in rats with heart failure with preserved ejection fraction by blocking the transforming growth factor-β1 /Smads signaling pathway.
    Shi Y; Liu C; Xiong S; Yang L; Yang C; Qiao W; Liu Y; Liu S; Liu J; Dong G
    J Ethnopharmacol; 2023 Dec; 317():116849. PubMed ID: 37385575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
    Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
    Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
    Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
    Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats.
    Zhang W; Liu J; Fu Y; Ji H; Fang Z; Zhou W; Fan H; Zhang Y; Liao Y; Yang T; Wang X; Yuan W; Chen X; Dong YF
    Front Pharmacol; 2020; 11():600953. PubMed ID: 33519461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-β1/Smads Pathway.
    Wu M; Guo Y; Wu Y; Xu K; Lin L
    Front Pharmacol; 2021; 12():696472. PubMed ID: 34135764
    [No Abstract]   [Full Text] [Related]  

  • 14. Study on the Efficacy of Sacubitril/Valsartan in Patients with Heart Failure with Preserved Ejection Fraction Undergoing Peritoneal Dialysis.
    Sheng Y; Ma X; Liu Y; Yang X; Sun F
    Cardiology; 2023; 148(5):385-394. PubMed ID: 37253340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.
    Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Solomon SD; Starling RC; Velazquez EJ; Williamson K; Zieroth S; Braunwald E
    J Card Fail; 2023 Jun; 29(6):922-930. PubMed ID: 36796671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qishen granule attenuates cardiac fibrosis by regulating TGF-β /Smad3 and GSK-3β pathway.
    Zeng Z; Wang Q; Yang X; Ren Y; Jiao S; Zhu Q; Guo D; Xia K; Wang Y; Li C; Wang W
    Phytomedicine; 2019 Sep; 62():152949. PubMed ID: 31102891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
    Jia R; Zhang X; Xu Y; Zheng Z; Jiang L; Zhang X; Sun C; Wu X; Li S; Raj A; Sun D
    Eur J Pharmacol; 2022 Aug; 928():175053. PubMed ID: 35709921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
    Myakala K; Jones BA; Wang XX; Levi M
    Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/Valsartan inhibits M1 type macrophages polarization in acute myocarditis by targeting C-type natriuretic peptide.
    Liu C; Long Q; Yang H; Yang H; Tang Y; Liu B; Zhou Z; Yuan J
    Biomed Pharmacother; 2024 May; 174():116535. PubMed ID: 38581923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction.
    Moraña-Fernández S; Vázquez-Abuín X; Aragón-Herrera A; Anido-Varela L; García-Seara J; Otero-García Ó; Rodríguez-Penas D; Campos-Toimil M; Otero-Santiago M; Rodrigues A; Gonçalves A; Pereira Morais J; Alves IN; Sousa-Mendes C; Falcão-Pires I; González-Juanatey JR; Feijóo-Bandín S; Lago F
    Biochem Pharmacol; 2024 Dec; 230(Pt 1):116571. PubMed ID: 39424202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.